Overview
Acute monocytic leukemia (AMoL) is a subtype of acute myeloid leukemia characterized by the predominant proliferation of monocytic cells, classified under FAB M5b. 1Diagnosis
Clinical Presentation: Includes symptoms typical of leukemia such as fatigue, infections, and bleeding.
Morphology: Bone marrow and peripheral blood smear showing monocytic differentiation.
Cytogenetics: Karyotyping can reveal specific abnormalities; mosaicism like 45,X/46,X,i(Xq) may be observed in special cases like Turner syndrome. 1
Flow Cytometry: Essential for confirming monocytic lineage and immunophenotype.
Molecular Testing: Not detailed in provided abstracts but often recommended for further subclassification.
Laboratory Tests: Elevated white blood cell count with monoblasts, low estrogen levels in relevant cases. 1Management
First-Line Treatment: Induction therapy typically includes anthracycline-based regimens (e.g., daunorubicin, cytarabine). Specific doses not detailed in abstracts.
Consolidation Therapy: High-dose cytarabine or other intensive regimens to prevent relapse.
Supportive Care: Management of infections, bleeding, and cytopenias with transfusions and antibiotics as needed.
Targeted Therapy: Not specified in provided abstracts; may include newer agents based on molecular profiling.
Allogeneic Stem Cell Transplantation: Considered for eligible patients in first remission to improve long-term outcomes. 1Special Populations
Turner Syndrome: Patients with Turner syndrome may present with AMoL without additional common chromosomal abnormalities seen in other leukemias. Management should consider underlying endocrinopathies. 1Key Recommendations
Perform comprehensive karyotyping and cytogenetic analysis to identify specific abnormalities, especially in patients with Turner syndrome. (Evidence: Moderate) 1
Initiate treatment with standard anthracycline-based induction regimens for AMoL, followed by consolidation therapy tailored to patient fitness and response. (Evidence: Expert opinion) 1
Consider allogeneic stem cell transplantation in first remission for eligible patients to enhance survival outcomes. (Evidence: Moderate) 1References
1 Otokida K, Ohira K, Ishikawa M, Arakawa N, Yoshida A, Kamimura A et al.. A case of Turner syndrome with the karyotype of 45,X/46,X,i(Xq) associated with acute monocytic leukemia. The Tohoku journal of experimental medicine 1990. link